EUVIMEDEUVIMED entdecken
Crossref

Isoimperatorin Inhibits Angiogenesis by Suppressing VEGFR2 Signaling Pathway

Yating Xu, Di Xia, Shan Deng, Minglu Liang iD

Cardiovascular Drugs and Therapy · 2024

DOI: 10.1007/s10557-024-07561-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiovascular Drugs and Therapy, 2024. Verfasst von Yating Xu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinic Center of Human Gene Research, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Ave, Wuhan,…. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor Receptor-2, Angiogenesis Inhibitors, Furocoumarins, Human Umbilical Vein Endothelial Cells. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Hubei Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Angiogenesis involves in many pathological processes, including tumor metastasis, diabetic retinopathy, and rheumatoid arthritis. Therefore, identifying therapeutic drugs that target angiogenesis may be a promising strategy for disease treatment. Isoimperatorin is a furanocoumarin with anti-inflammatory and anti-microbial effects. However, the impacts of isoimperatorin on angiogenesis and its underlying mechanisms remain unclear. This study aimed to verify its effects on vascular endothelial growth factor (VEGF)-induced endothelial angiogenesis. METHODS: We employed various assays including 5-ethynyl-2'-deoxyuridine incorporation assay, transwell migration assay, wound healing assay, tube formation assay, and Western blot to evaluate the effects of isoimperatorin on angiogenesis in vitro. Additionally, we utilized Western blot and immunofluorescence analysis to examine the activation of vascular endothelial growth factor receptor (VEGFR) 2 and its downstream signaling pathways following isoimperatorin treatment. To further validate the anti-angiogenic effects of isoimperatorin in vivo, we conducted a matrigel plug assay and established an orthotopic tumor model. RESULTS: We demonstrated that pretreatment with isoimperatorin inhibited VEGF-induced endothelial cell proliferation, migration, and tube formation. Isoimperatorin also suppressed angiogenesis in vivo in a matrigel plug assay and in an orthotopic tumor model. Our results revealed that isoimperatorin exhibited anti-angiogenic effects via inhibiting VEGFR2 and its downstream signaling pathways activation. CONCLUSIONS: Our study showed that isoimperatorin suppressed angiogenesis by targeting the VEGFR2 signaling pathway and could be a potential therapeutic agent for targeting angiogenesis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vascular Endothelial Growth Factor Receptor-2Angiogenesis InhibitorsFurocoumarinsHuman Umbilical Vein Endothelial CellsNeovascularization, PathologicNeovascularization, PhysiologicAnimalsSignal TransductionHumansCell MovementCell ProliferationVascular Endothelial Growth Factor AMice, NudeMiceAngiogenesis

Stichwörter der Autor:innen

AngiogenesisIsoimperatorinVEGFVEGFR2

Substanzen

Vascular Endothelial Growth Factor Receptor-2Angiogenesis InhibitorsFurocoumarinsKDR protein, humanVascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • Clinic Center of Human Gene Research, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Ave, Wuhan, 430022, China.
  • Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Hubei Key Laboratory of Metabolic Abnormalities and Vascular Aging, Huazhong University of Science and Technology, Wuhan, China.
  • Cardiovascular Center, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Clinic Center of Human Gene Research, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Ave, Wuhan, 430022, China. dengshan1020@qq.com.
  • Hubei Key Laboratory of Metabolic Abnormalities and Vascular Aging, Huazhong University of Science and Technology, Wuhan, China. dengshan1020@qq.com.

ORCID-Profile: Minglu Liang

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Hubei Province

Zitieren

APA

Xu, Y., Xia, D., Deng, S., & Liang, M. (2024). Isoimperatorin Inhibits Angiogenesis by Suppressing VEGFR2 Signaling Pathway. Cardiovascular Drugs and Therapy. https://doi.org/10.1007/s10557-024-07561-5

Vancouver

Xu Y, Xia D, Deng S, Liang M. Isoimperatorin Inhibits Angiogenesis by Suppressing VEGFR2 Signaling Pathway. Cardiovascular Drugs and Therapy. 2024. doi:10.1007/s10557-024-07561-5

BibTeX
@article{Xu2024,
  author = {Xu, Yating and Xia, Di and Deng, Shan and Liang, Minglu},
  title = {Isoimperatorin Inhibits Angiogenesis by Suppressing VEGFR2 Signaling Pathway},
  journal = {Cardiovascular Drugs and Therapy},
  year = {2024},
  doi = {10.1007/s10557-024-07561-5}
}
Kostenlos starten →